Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy application has been examined.
The temporary subsidy covers patients who are already being treated with Tepmetko or who are already being treated with a licensed medicine that is being replaced by Tepmetko.
